How to Develop a Global Clinical Study Budget Like a Pro, New Webinar Hosted by Xtalks

How to Develop a Global Clinical Study Budget Like a Pro, New Webinar Hosted by Xtalks

Press Release (ePRNews.com) - TORONTO - Nov 21, 2018 - Clinical research is a notoriously cost-sensitive industry. The Tufts Center for the Study of Drug Development estimated the average cost of bringing a new drug to market to be over $2 billion – and with clinical trial costs on the rise, it’s more important than ever to take a smart approach to developing study budgets. This is especially true when taking on global clinical trials.

On Monday, December 10, 2018 at 1pm EST, join Medrio and DĂ©bora S. Araujo, founder and CEO of the pharmaceutical skill development company ClinBiz, for a brand-new live webinar: How to Develop a Global Clinical Study Budget Like a Pro. The session will offer organizations conducting clinical trials insight into a host of critical issues related to various aspects of clinical study budgets, and will be a key resource for any organization looking to increase the cost-efficiency of their clinical trials.

Key takeaways:

  • What questions to ask during the clinical study budget development stage to avoid pushback from senior management at the budget approval stage
  • What to include in a clinical study budget package so the budget gets approval quickly
  • How to use benchmarks to achieve bulletproof clinical study budget estimates

In the current environment, organizations must do whatever possible to mitigate the costs of bringing new products to market approval.

To register for this complimentary webinar visit: How to Develop a Global Clinical Study Budget Like a Pro.

ABOUT CLINBIZ

ClinBiz provides an online educational platform with a dedicated YouTube channel, podcast, blog, annual conference and upcoming online courses where clinical research professionals can stay connected and updated on the latest topics, trends and technologies related to the business aspects of clinical trials.

ABOUT MEDRIO

Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more.  Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit https://medrio.com/.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Sarah Hand

Tel: +1 (416) 977-6555 ext 224

Email: shand@xtalks.com

Source : Xtalks
SHARE :  
Business Info :
Xtalks

You may also like this  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.